RCM
VNDA icon

RA Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

RA Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-243,971
Closed -$4.37M – 31
2017
Q3 		$4.37M Buy
+243,971
New +$4.08M 0.39% 24

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RA Capital Management's VNDA Position: Q4 2017 in Review

RA Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2017, closing a stake of 243,971 shares — an estimated $4.37M sold.

RA Capital Management first reported a position in VNDA in Q3 2017 and held it in 1 quarter. The position peaked at $4.37M in Q3 2017. 125 funds tracked by Wall St. Rank hold VNDA as of Q4 2017.

  • RA Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • RA Capital Management sold 243,971 Vanda Pharmaceuticals shares in Q4 2017, an estimated $4.37M.
  • RA Capital Management first reported a position in Vanda Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • RA Capital Management's Vanda Pharmaceuticals position peaked at $4.37M in Q3 2017.
  • 125 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2017.

Based on RA Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.